Virginia Commonwealth University

VCU Massey Cancer Center

Massey researchers find that failure to expand ACA Medicaid coverage would widen disparities in screening uninsured and low-income women for breast and cervical cancer

Virginia Commonwealth University Massey Cancer Center researchers recently conducted a study that found low-income and uninsured women in states that are not expanding their Affordable Care Act (ACA) Medicaid coverage are less likely to receive breast and cervical cancer screenings compared to states that are implementing expansions.

Continue reading →

Advanced viral gene therapy eradicates prostate cancer in preclinical experiments

Paul Fisher at his desk.

Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer’s growth.

Continue reading →

Cancer Cell Signaling program welcomes Francesco S. Celi as research member

VCU Massey Cancer Center welcomes Francesco S. Celi, M.D., M.H.Sc., as a research member in the Cancer Cell Signaling program. Celi joined VCU last year as a professor of internal medicine and chair of the Division of Endocrinology and Metabolism. Since then, he has been a member of Massey’s Metabolism and Cancer Research Working Group.

Continue reading →

Massey researcher awarded ACS grant to improve communication between African Americans and physicians about clinical trials

Virginia Commonwealth University Massey Cancer Center researcher Richard Brown, Ph.D., has been awarded a nearly $1 million Research Scholar Grant from the American Cancer Society to test tailored messaging that would aid African Americans in making decisions about enrolling in therapeutic cancer clinical trials.

Continue reading →

Massey researcher receives NIH grant to study unknown factors controlling adaptive low-oxygen cell response that aids in cancer growth

Massey researcher Keith Baker, Ph.D., received a $219,030 Exploratory/Developmental Research (R21) grant from the National Institutes of Health to identify the components that help cells adapt and survive in low-oxygen conditions that occur in novel cell signaling pathways. Low-oxygen responses typically occur in the Hypoxia-Inducible Factor (HIF) pathway, but Baker will be looking at the responses that occur in independent signaling pathways. This study will be the first of its kind that will specifically assess HIF-independent low-oxygen responses in an intact organism.

Continue reading →